Find Tafamidis Meglumine manufacturers, exporters & distributors on PharmaCompass

Tafamidis Meglumine

Inke Tafamidis meglumine

Contact Supplier

Farmak Tafamidis Meglumine

Contact Supplier

Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

Contact Supplier

Nuray Tafamidis Meglumine

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

xyz-pharma-m-2025-01-06

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

25 API Suppliers, 13 USDMF, 4 EU WC, 10 NDC API, 20 Listed Suppliers, $ API Reference Price

25 API Suppliers
13 USDMF
4 EU WC
10 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

3 Intermediates Suppliers

3 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 1 FDA Orange Book, 2 Europe, 1 Canada, 1 Listed Dossiers

5 FDF Dossiers
1 FDA Orange Book
2 Europe
1 Canada
1 Listed Dossiers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 17 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
17 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Finished Drug Prices, 5 Annual Reports

globalSalesInformation
1 US Medicaid Prescriptions
1 Finished Drug Prices
5 Annual Reports

MARKET PLACE

2 APIs, 1 FDF Dossiers

marketPlace
2 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 2 US Exclusivities

patents
2 US Patents
2 US Exclusivities

Inke Tafamidis Meglumine

Synopsis

ACTIVE PHARMA INGREDIENTS

25

API Suppliers

13

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

4

EU WC

0

KDMF

10

NDC API

0

VMF

20

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 18,074

MARKET PLACE

2

API

1

FDF

3INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

5

FDF Dossiers

1

FDA Orange Book

FDA (Orange Book)

2

Europe

1

Canada

0

Australia

0

South Africa

1

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

2

US Patents

2

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

2

Data Compilation #PharmaFlow

1

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

17

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

109,330,317

Annual Reports (USD Million)

9,544

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: Vyndaqel, 951395-08-7, Fx-1006a, Fx1006a, Fx 1006a, Zu7cf08a1a

Molecular Formula

C₂₁H₂₄Cl₂N₂O₈

Molecular Weight

503.3 g/mol

InChI Key

DQJDBUPLRMRBAB-WZTVWXICSA-N

FDA UNII

ZU7CF08A1A

Tafamidis Meglumine

Tafamidis Meglumine is a soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential disease-modifying activity. Tafamidis binds to and stabilizes wild-type and variant (V122I) transthyretin (TTR), thereby preventing tetramer dissociation into monomers; this prevents misfolding of the TTR protein and inhibits the formation of TTR amyloid fibrils and the subsequent deposition of these insoluble protein clusters in peripheral nerve tissues and organs. TTR is a 127 amino acid transport protein for thyroxine and retinol and is secreted by the liver.

1 2D Structure

Tafamidis Meglumine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol

2.1.2 InChI

InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

2.1.3 InChI Key

DQJDBUPLRMRBAB-WZTVWXICSA-N

2.1.4 Canonical SMILES

CNCC(C(C(C(CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

2.1.5 Isomeric SMILES

CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

2.2 Other Identifiers

2.2.1 UNII

ZU7CF08A1A

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Fx 1006a

2. Fx-1006a

3. Fx1006a

4. Tafamidis

5. Vyndamax

6. Vyndaqel

2.3.2 Depositor-Supplied Synonyms

1. Vyndaqel

2. 951395-08-7

3. Fx-1006a

4. Fx1006a

5. Fx 1006a

6. Zu7cf08a1a

7. Chebi:79345

8. 951395-08-7 (meglumine)

9. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate

10. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic Acid

11. Unii-zu7cf08a1a

12. Tafamidis Meglumine [usan]

13. Tafamidis Meglumine [usan:inn]

14. Vyndaqel (tn)

15. Chembl2105675

16. Schembl14783506

17. Tafamidis Meglumine [mi]

18. Tafamidis Meglumine (jan/usan)

19. Dtxsid50915094

20. Tafamidis Meglumine [jan]

21. Ex-a3550

22. Hy-14852a

23. Mfcd28502032

24. Tafamidis Meglumine [who-dd]

25. Akos037649321

26. At18247

27. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate

28. Tafamidis Meglumine [orange Book]

29. Bs-18043

30. Cs-0045567

31. Pf-06291826

32. D09674

33. Q27148396

34. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate

35. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)

36. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)hexitol (1/1)

37. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol

38. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)

39. D-gluco-2,3,4,5,6-pentahydroxy-n-methylhexan-1-aminium 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylate

2.4 Create Date

2008-10-20

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₄Cl₂N₂O₈
Molecular Weight	503.3 g/mol
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	8
Exact Mass	502.0909711 g/mol
Monoisotopic Mass	502.0909711 g/mol
Topological Polar Surface Area	177 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	506
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in amyloidosis.

Neuropathic heredofamilial amyloidosis

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

Fx-1006A is a first-in-class, disease-modifying compound that is designed to inhibit the formation of amyloid deposits by preventing the misfolding and deposition of the transthyretin protein (TTR), which is associated with amyloidosis.

API SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"TAFAMIDIS MEGLUMINE","year":"2021","qtr":"Q1","strtotime":1614709800,"product":"TAFAMIDIS MEGLUMINE","address":"25, 12TH CROSS STREET, SHASTRI NAGAR,","city":"CHENNAI\/TAMILNADU","supplier":"NURAY CHEMICALS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"THE PURCHASE MANAGER","customerCountry":"ISRAEL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"9922.1","totalValueFC":"9819.7","currency":"USD","unitRateINR":714890,"date":"03-Mar-2021","totalValueINR":"714890","totalValueInUsd":"9819.7","indian_port":"MADRAS AIR","hs_no":"29221990","bill_no":"9075200","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRAS AIR","supplierAddress":"25, 12TH CROSS STREET, SHASTRI NAGAR,, CHENNAI\/TAMILNADU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"TAFAMIDIS MEGLUMINE","year":"2021","qtr":"Q2","strtotime":1622140200,"product":"TAFAMIDIS MEGLUMINE","address":"25, 12TH CROSS STREET, SHASTRI NAGAR,","city":"CHENNAI\/TAMILNADU","supplier":"NURAY CHEMICALS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"THE PURCHASE MANAGER","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.36","actualQuantity":"0.36","unit":"KGS","unitRateFc":"14876.1","totalValueFC":"5267.7","currency":"USD","unitRateINR":1071822.2222222222,"date":"28-May-2021","totalValueINR":"385856","totalValueInUsd":"5267.7","indian_port":"MADRAS AIR","hs_no":"29349990","bill_no":"2059118","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRAS AIR","supplierAddress":"25, 12TH CROSS STREET, SHASTRI NAGAR,, CHENNAI\/TAMILNADU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1622658600,"product":"TAFAMIDIS MEGLUMINE","address":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"TATEYAMA KASEI CO LTD","customerCountry":"JAPAN","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"11000","totalValueFC":"543.9","currency":"USD","unitRateINR":800000,"date":"03-Jun-2021","totalValueINR":"40000","totalValueInUsd":"543.9","indian_port":"DELHI AIR","hs_no":"29371900","bill_no":"2195068","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1628188200,"product":"TAFAMIDIS MEGLUMINE","address":"25, 12TH CROSS STREET, SHASTRI NAGAR,","city":"CHENNAI\/TAMILNADU","supplier":"NURAY CHEMICALS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"THE PURCHASE MANAGER","customerCountry":"GERMANY","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"15228.5","totalValueFC":"44381.1","currency":"USD","unitRateINR":1097211.6666666667,"date":"06-Aug-2021","totalValueINR":"3291635","totalValueInUsd":"44381.1","indian_port":"MADRAS AIR","hs_no":"29221990","bill_no":"3673438","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRAS AIR","supplierAddress":"25, 12TH CROSS STREET, SHASTRI NAGAR,, CHENNAI\/TAMILNADU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642703400,"product":"TAFAMIDIS MEGLUMINE","address":"8-3-166\/7\/1, HETERO HOUSE,","city":"HYDERABAD, AP.","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"PRAHA","customer":"ZENTIVA","customerCountry":"CZECH REPUBLIC","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"13926","totalValueFC":"13758.9","currency":"USD","unitRateINR":1024950,"date":"21-Jan-2022","totalValueINR":"1024950","totalValueInUsd":"13758.9","indian_port":"Vizag-HIPL SEZ","hs_no":"29189990","bill_no":"4000050","productDescription":"API","marketType":"REGULATED MARKET","country":"CZECH REPUBLIC","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"8-3-166\/7\/1, HETERO HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646332200,"product":"TAFAMIDIS MEGLUMINE (NOC NO:2319530 \/TS","address":"PLOT NO.B-4, IDA, GANDHI NAGAR,,ME DCHAL-MALKAJGIRI DISTRICT,","city":"HYDERABD,TELANGANA","supplier":"VIRUPAKSHA ORGANICS","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"TO THE ORDER OF","customerCountry":"JAPAN","quantity":"0.03","actualQuantity":"30","unit":"GMS","unitRateFc":"600","totalValueFC":"17580.8","currency":"USD","unitRateINR":44666.666666666664,"date":"04-Mar-2022","totalValueINR":"1340000","totalValueInUsd":"17580.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"8691629","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.B-4, IDA, GANDHI NAGAR,,ME DCHAL-MALKAJGIRI DISTRICT,, HYDERABD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1648837800,"product":"TAFAMIDIS MEGLUMINE","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"NEWARK","customer":"AUCTA PHARMACEUTICALS","customerCountry":"UNITED STATES","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"17812.5","totalValueFC":"35507.5","currency":"USD","unitRateINR":1339500,"date":"02-Apr-2022","totalValueINR":"2679000","totalValueInUsd":"35507.5","indian_port":"Dahez-SEZ","hs_no":"29332990","bill_no":"4004377","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649097000,"product":"TAFAMIDIS MEGLUMINE","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"PRODUCTS ESZE CORP","customerCountry":"JAPAN","quantity":"0.09","actualQuantity":"85","unit":"GMS","unitRateFc":"42.8","totalValueFC":"3621.8","currency":"USD","unitRateINR":3214.8000000000002,"date":"05-Apr-2022","totalValueINR":"273258","totalValueInUsd":"3621.8","indian_port":"Dahez-SEZ","hs_no":"29332990","bill_no":"4004458","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670524200,"product":"TAFAMIDIS MEGLUMINE","address":"SANALI INFO PARK, 8-2-120\/113,ROAD NO.2, BANJARA HILLS","city":"HYDERABAD,TELANGANA","supplier":"NEULAND LABORATORIES","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"0.08","actualQuantity":"0.075","unit":"KGS","unitRateFc":"60000","totalValueFC":"4295.8","currency":"USD","unitRateINR":4720000,"date":"09-Dec-2022","totalValueINR":"354000","totalValueInUsd":"4295.8","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"6049942","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"SANALI INFO PARK, 8-2-120\/113,ROAD NO.2, BANJARA HILLS, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690309800,"product":"TAFAMIDIS MEGLUMINE","address":"25, 12TH CROSS STREET, SHASTRI NAGAR,","city":"CHENNAI\/TAMILNADU","supplier":"NURAY CHEMICALS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"THE PURCHASE MANAGER..\"","customerCountry":"ARGENTINA","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"20000","totalValueFC":"1837.2","currency":"USD","unitRateINR":1509998.4899999998,"date":"26-Jul-2023","totalValueINR":"150999.849","totalValueInUsd":"1837.2","indian_port":"MADRAS AIR","hs_no":"29372900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRAS AIR","supplierAddress":"25, 12TH CROSS STREET, SHASTRI NAGAR,, CHENNAI\/TAMILNADU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691087400,"product":"TAFAMIDIS MEGLUMINE","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"GREECE","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"49328.4","totalValueFC":"4877.1","currency":"USD","unitRateINR":4040000.0550000002,"date":"04-Aug-2023","totalValueINR":"404000.0055","totalValueInUsd":"4877.1","indian_port":"HYDERABAD ICD","hs_no":"29221990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708021800,"product":"TAFAMIDIS MEGLUMINE","address":"PLOT NO. 193, HOUSE NO. 5-35\/50,","city":"HYDERABAD, AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"RENATA LIMITED","customerCountry":"BANGLADESH","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"20000","totalValueFC":"29678.1","currency":"USD","unitRateINR":1641666.6666666667,"date":"16-Feb-2024","totalValueINR":"2462500","totalValueInUsd":"29678.1","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"7574643","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 193, HOUSE NO. 5-35\/50,, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717957800,"product":"TAFAMIDIS MEGLUMINE-STAGE-I","address":"PLOT NO. 193, HOUSE NO. 5-35\/50,","city":"HYDERABAD, AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"RENATA LIMITED","customerCountry":"BANGLADESH","quantity":"0.00","actualQuantity":"0.25","unit":"GMS","unitRateFc":"14000","totalValueFC":"3449.6","currency":"USD","unitRateINR":1151868.24,"date":"10-Jun-2024","totalValueINR":"287967.06","totalValueInUsd":"3449.6","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"1564765","productDescription":"Intermediate","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 193, HOUSE NO. 5-35\/50,, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720377000,"product":"TAFAMIDIS MEGLUMINE","address":"PLOT NO. 193, HOUSE NO. 5-35\/50,","city":"HYDERABAD, AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"RENATA LIMITED","customerCountry":"BANGLADESH","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"20000","totalValueFC":"39510.2","currency":"USD","unitRateINR":1651350,"date":"08-Jul-2024","totalValueINR":"3302700","totalValueInUsd":"39510.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"2248361","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 193, HOUSE NO. 5-35\/50,, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637692200,"product":"TAFAMIDIS MEGLUMINE","address":"SURVEY NO.42, GADDAPOTHARAM,KAZIPA LLY IND AREA, SANGAREDDY DIST","city":"GADDAPOTHARAM HYD,TELANGANA","supplier":"ALFRED E TIEFENBACHER GMBH","supplierCountry":"ITALY","foreign_port":"NA","customer":"ALFRED E TIEFENBACHER GMBH","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10530","totalValueFC":"6051.8","currency":"EUR","unitRateINR":"901368","date":"24-Nov-2021","totalValueINR":"450684","totalValueInUsd":"6051.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"6384540","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SURVEY NO.42, GADDAPOTHARAM,KAZIPA LLY IND AREA, SANGAREDDY DIST"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1640802600,"product":"TAFAMIDIS MEGLUMINE","address":"SURVEY NO.42, GADDAPOTHARAM,KAZIPA LLY IND AREA, SANGAREDDY DIST","city":"GADDAPOTHARAM HYD,TELANGANA","supplier":"ALFRED E TIEFENBACHER GMBH","supplierCountry":"SPAIN","foreign_port":"N\/A","customer":"ALFRED E TIEFENBACHER GMBH","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10530","totalValueFC":"6121.8","currency":"EUR","unitRateINR":"923481","date":"30-Dec-2021","totalValueINR":"461740.5","totalValueInUsd":"6121.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"6894002","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"","customerAddress":"SURVEY NO.42, GADDAPOTHARAM,KAZIPA LLY IND AREA, SANGAREDDY DIST"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1654885800,"product":"TAFAMIDIS MEGLUMINE MICRONIZED","address":"SURVEY NO.42, GADDAPOTHARAM,KAZIPA LLY IND AREA, SANGAREDDY DIST","city":"GADDAPOTHARAM HYD,TELANGANA","supplier":"CHEMO","supplierCountry":"ITALY","foreign_port":"NA","customer":"ALFRED E TIEFENBACHER GMBH","customerCountry":"INDIA","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"10000","totalValueFC":"12959","currency":"EUR","unitRateINR":"842500","date":"11-Jun-2022","totalValueINR":"1011000","totalValueInUsd":"12959","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"9065267","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Micronized","supplierPort":"NA","supplierAddress":"","customerAddress":"SURVEY NO.42, GADDAPOTHARAM,KAZIPA LLY IND AREA, SANGAREDDY DIST"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

01

Dr. Reddy's Laboratories

India

CPhI WW Frankfurt

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

India

Digital Content

Regulatory Info : Lead Market Dossiers- Under De...

Registration Country : India

Tafamidis Meglumine

Brand Name :

Dosage Form : Oral Solid Dosage Form

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info : Lead Market Dossiers- Under De...

Registration Country : India

Dr Reddy Company Banner

Product Web Link

Digital Content

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024. Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each. The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders). View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453 US$ 3,21,920 Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427 US$ 2,31,952 FDF—Foreign US$ 2,35,427 US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629 US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852 US$ 7,56,666 Small business generic drug applicant US$ 1,72,963 US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.

Impressions: 6681

STOCK RECAP #PipelineProspector

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

01

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

02

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

03

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

04

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

05

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

06

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

07

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

08

Brand Name : Vyndaqel

Country

PharmaVenue

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Finished Drug Prices

01

Brand Name : Vyndaqel

U.S.A

PharmaVenue

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

01

Brand Name : Vyndaqel/Vyndamax

Tafamidis Meglumine

PharmaVenue

Not Confirmed

02

Brand Name : Vyndaqel/Vyndamax

Tafamidis Meglumine

PharmaVenue

Not Confirmed

03

Brand Name : Vyndaqel/Vyndamax

Tafamidis Meglumine

PharmaVenue

Not Confirmed

04

Brand Name : Vyndaqel/Vyndamax

Tafamidis Meglumine

PharmaVenue

Not Confirmed

05

Brand Name : Vyndaqel/Vyndamax

Tafamidis Meglumine

PharmaVenue

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

Tafamidis Meglumine (1.5 kg) API needed in Turkey [ENA21603]

A company that focuses on development and manufacturing of various finished formulations is looking for suppliers of Tafamidis Meglumine (1.5 kg) API for both development & commercial purposes. The suppliers must support this enquiry with CEP, DMF, GMP & CoA.

Reply

31 Dec 2024

Tafamidis Meglumine API needed in India [ENA09821]

A global healthcare leader with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines is looking for suppliers of Tafamidis Meglumine API for development purposes. The suppliers must support this enquiry with USDMF.

Reply

26 Feb 2021

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

Tafamidis Meglumine (20 mg) Capsules needed in India [ENA08314]

Allied Overseas Exim India, a sourcing company based in India that deals in various pharmaceutical products is looking for suppliers of Tafamidis Meglumine (20 mg) Capsules. The required quantity is 900 packs of 30 capsules. Interested suppliers can contact them via their email: alliedoverseasexim@gmail.com.

Reply

21 Aug 2020

PharmaCompass

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Tafamidis Meglumine Manufacturers

A Tafamidis Meglumine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tafamidis Meglumine, including repackagers and relabelers. The FDA regulates Tafamidis Meglumine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tafamidis Meglumine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Tafamidis Meglumine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Tafamidis Meglumine Suppliers

A Tafamidis Meglumine supplier is an individual or a company that provides Tafamidis Meglumine active pharmaceutical ingredient (API) or Tafamidis Meglumine finished formulations upon request. The Tafamidis Meglumine suppliers may include Tafamidis Meglumine API manufacturers, exporters, distributors and traders.

click here to find a list of Tafamidis Meglumine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Tafamidis Meglumine USDMF

A Tafamidis Meglumine DMF (Drug Master File) is a document detailing the whole manufacturing process of Tafamidis Meglumine active pharmaceutical ingredient (API) in detail. Different forms of Tafamidis Meglumine DMFs exist exist since differing nations have different regulations, such as Tafamidis Meglumine USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Tafamidis Meglumine DMF submitted to regulatory agencies in the US is known as a USDMF. Tafamidis Meglumine USDMF includes data on Tafamidis Meglumine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tafamidis Meglumine USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Tafamidis Meglumine suppliers with USDMF on PharmaCompass.

Tafamidis Meglumine WC

A Tafamidis Meglumine written confirmation (Tafamidis Meglumine WC) is an official document issued by a regulatory agency to a Tafamidis Meglumine manufacturer, verifying that the manufacturing facility of a Tafamidis Meglumine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tafamidis Meglumine APIs or Tafamidis Meglumine finished pharmaceutical products to another nation, regulatory agencies frequently require a Tafamidis Meglumine WC (written confirmation) as part of the regulatory process.

click here to find a list of Tafamidis Meglumine suppliers with Written Confirmation (WC) on PharmaCompass.

Tafamidis Meglumine NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tafamidis Meglumine as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Tafamidis Meglumine API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Tafamidis Meglumine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Tafamidis Meglumine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tafamidis Meglumine NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Tafamidis Meglumine suppliers with NDC on PharmaCompass.

Tafamidis Meglumine GMP

Tafamidis Meglumine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Tafamidis Meglumine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tafamidis Meglumine GMP manufacturer or Tafamidis Meglumine GMP API supplier for your needs.

Tafamidis Meglumine CoA

A Tafamidis Meglumine CoA (Certificate of Analysis) is a formal document that attests to Tafamidis Meglumine's compliance with Tafamidis Meglumine specifications and serves as a tool for batch-level quality control.

Tafamidis Meglumine CoA mostly includes findings from lab analyses of a specific batch. For each Tafamidis Meglumine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Tafamidis Meglumine may be tested according to a variety of international standards, such as European Pharmacopoeia (Tafamidis Meglumine EP), Tafamidis Meglumine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tafamidis Meglumine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Menu

Post Enquiry

Market Place

Search